More on KYNB
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.25 |
|
|||
| Open | $7.25 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $7.25 | ||||
| Day Low | $7.25 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 5,760 | ||||
- Lake Street Starts Kyntra Bio (KYNB) at Buy
- Oppenheimer Reiterates Outperform Rating on Kyntra Bio (KYNB)
- Oppenheimer says this biotech name offers an "attractive buying opportunity"
- Kyntra Bio, Inc. (KYNB) Tops Q2 EPS by 614c
- Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
- Kyntra Bio to Report Second Quarter 2026 Financial Results
- Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35
- Kyntra Bio presents roxadustat data showing transfusion improvements in MDS
- Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
- Rodman & Renshaw Starts Kyntra Bio (KYNB) at Buy
Entities mentioned with KYNB
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Rodman & Renshaw | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
